J 2021

Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries

KOLONICS-FARKAS, A. M., Martina STERCLOVA, Nesrin MOGULKOC, Katarzyna LEWANDOWSKA, Veronika MULLER et. al.

Základní údaje

Originální název

Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries

Autoři

KOLONICS-FARKAS, A. M., Martina STERCLOVA (203 Česká republika), Nesrin MOGULKOC, Katarzyna LEWANDOWSKA, Veronika MULLER (garant), Marta HAJKOVA, Mordechai KRAMER, Dragana JOVANOVIC, Jasna TEKAVEC-TRKANJEC, Michael STUDNICKA, Natalia STOEVA, Simona LITTNEROVÁ (203 Česká republika, domácí) a Martina VASAKOVA (203 Česká republika)

Vydání

FRONTIERS IN MEDICINE, LAUSANNE, FRONTIERS MEDIA SA, 2021, 2296-858X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.058

Kód RIV

RIV/00216224:14110/21:00124163

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000745232800001

Klíčová slova anglicky

IPF; treatment; regional accessibility; registry analysis; Central-Eastern Europe

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 15. 2. 2022 13:19, Mgr. Tereza Miškechová

Anotace

V originále

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease with poor prognosis. The diagnosis and treatment possibilities are dependent on the health systems of countries. Hence, comparison among countries is difficult due to data heterogeneity. Our aim was to analyse patients with IPF in Central and Eastern Europe using the uniform data from the European Multipartner IPF registry (EMPIRE), which at the time of analysis involved 10 countries. Newly diagnosed IPF patients (N = 2,492, between March 6, 2012 and May 12, 2020) from Czech Republic (N = 971, 39.0%), Turkey (N = 505, 20.3%), Poland (N = 285, 11.4%), Hungary (N = 216, 8.7%), Slovakia (N = 149, 6.0%), Israel (N = 120, 4.8%), Serbia (N = 95, 3.8%), Croatia (N = 87, 3.5%), Austria (N = 55, 2.2%), and Bulgaria (N = 9, 0.4%) were included, and Macedonia, while a member of the registry, was excluded from this analysis due to low number of cases (N = 5) at this timepoint. Baseline characteristics, smoking habit, comorbidities, lung function values, CO diffusion capacity, high-resolution CT (HRCT) pattern, and treatment data were analysed. Patients were significantly older in Austria than in the Czech Republic, Turkey, Hungary, Slovakia, Israel, and Serbia. Ever smokers were most common in Croatia (84.1%) and least frequent in Serbia (39.2%) and Slovakia (42.6%). The baseline forced vital capacity (FVC) was >80% in 44.6% of the patients, between 50 and 80% in 49.3%, and 80% were registered in Poland (63%), while the least in Israel (25%). A typical usual interstitial pneumonia (UIP) pattern was present in 67.6% of all patients, ranging from 43.5% (Austria) to 77.2% (Poland). The majority of patients received antifibrotic therapy (64.5%); 37.4% used pirfenidone (range 7.4-39.8% between countries); and 34.9% nintedanib (range 12.6-56.0% between countries) treatment. In 6.8% of the cases, a therapy switch was initiated between the 2 antifibrotic agents. Significant differences in IPF patient characteristics and access to antifibrotic therapies exist in EMPIRE countries, which needs further investigation and strategies to improve and harmonize patient care and therapy availability in this region.